Loading
A phase 1/2 trial of Ifinatamab deruxtecan, Atezolizumab, Carboplatin in small-cell lung cancer, run by Daiichi Sankyo, now recruiting.
A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03) is a phase 1/2 interventional study registered as NCT06362252 by Daiichi Sankyo, with 123 participants planned, started 2024-07-22 and due to reach its primary completion in 2026-09-30. Interventions recorded: Ifinatamab deruxtecan, Atezolizumab, Carboplatin. Conditions listed: Extensive Stage-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Ifinatamab deruxtecan, Daiichi Sankyo, Extensive-stage small-cell lung cancer, Antibody-drug conjugate (ADC).
Shares Ifinatamab deruxtecan, Extensive-stage small-cell lung cancer, Atezolizumab, Carboplatin.
Shares Extensive-stage small-cell lung cancer, Atezolizumab, Platinum agents, Carboplatin.
Shares Extensive-stage small-cell lung cancer, Atezolizumab, Platinum agents, Carboplatin.
Shares Ifinatamab deruxtecan, Atezolizumab, Antibody-drug conjugate (ADC), Small-cell lung cancer.
Shares Extensive-stage small-cell lung cancer, Atezolizumab, Platinum agents, Carboplatin.
Shares Extensive-stage small-cell lung cancer, Atezolizumab, Platinum agents, Carboplatin.
Shares Ifinatamab deruxtecan, Extensive-stage small-cell lung cancer, Antibody-drug conjugate (ADC), Small-cell lung cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/